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ABSTRACT 
 Although traditional renin-angiotensin system (RAS) antagonists including 
angiotensin converting-enzyme inhibitors (ACEIs) and angiotensin receptor blockers 
(ARBs) have revolutionized the treatment of cardiovascular disease (CVD), the pivotal 
PARADIGM-HF trial demonstrated that sacubitril/valsartan, an angiotensin receptor-
neprilysin inhibitor (ARNI), was superior to an angiotensin converting-enzyme inhibitor 
in reducing CV morbidity and mortality in patients with heart failure and a reduced 
ejection fraction (HFrEF). However, despite international regulatory approval and strong 
recommendations in the guidelines, uptake of sacubitril/valsartan has been disappointing. 
Sacubitril/valsartan is now the focus of a large program of clinical trials testing the 
hypothesis that ARNIs may supplant conventional RAS inhibitors across the spectrum of 
CVD, including hypertension, secondary prevention after myocardial infarction, and HF 
with a preserved ejection fraction (HFpEF). This review summarizes the existing 
evidence, knowledge gaps, and future directions of ARNIs in CVD based on discussions 
between clinical trialists, industry representatives, and regulatory authorities at the 2016 
Global CardioVascular Clinical Trialists Forum in Washington, D.C.   
Keywords: heart failure, reduced ejection fraction, angiotensin receptor-neprilysin 
inhibitor, sacubitril/valsartan 
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ABBREVIATIONS 
CVD = cardiovascular disease 
RAS = renin-angiotensin system 
ACEI = angiotensin converting-enzyme inhibitor 
ARB = angiotensin receptor blocker 
ARNI = angiotensin receptor-neprilysin inhibitor 
HFrEF = heart failure with a reduced ejection fraction 
HFpEF = heart failure with a preserved ejection fraction 
MI = myocardial infarction 
FDA = Food and Drug Administration 
EMA = European Medicines Agency 
NYHA = New York Heart Association 
BNP = b-type natriuretic peptide 
NT-proBNP = amino terminal pro b-type natriuretic peptide 
SBP = systolic blood pressure 
DBP = diastolic blood pressure 
eGFR = estimated glomerular filtration rate 
HR = hazard ratio 
CI = confidence interval 
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INTRODUCTION 
The prognosis of patients with CVD has been revolutionized by guideline-
directed medical therapies (1). Although traditional RAS antagonists, including ACEIs 
and ARBs, have been the cornerstone of therapy for CVD for several decades (2), the 
PARADIGM-HF trial, demonstrated that substitution of an ACEI (i.e. enalapril) with an 
ARNI (i.e. sacubitril/valsartan) led to a 20% relative reduction in the risk of CV death or 
HF hospitalization in patients with chronic, stable HFrEF (3, 4). As a result, the FDA and 
EMA approved sacubitril/valsartan (Table 1) and the ACC/AHA/HFSA and ESC 
updated their guidelines to reflect these new results (Table 2) (5, 6). In addition, Novartis 
initiated a large clinical trial program to find out whether ARNIs might be superior to 
ACEIs across the spectrum of CVD. The objective of this review is to critically evaluate 
the role of sacubitril/valsartan in CVD and to discuss completed, ongoing, and planned 
clinical trials in HFrEF, HFpEF, post-MI, and hypertension (Table 3).   
 
HEART FAILURE WITH A REDUCED EJECTION FRACTION 
PARADIGM-HF  
Study Overview 
 The PARADIGM-HF trial was designed to test the hypothesis that inhibiting 
neprilysin, thereby preventing the degradation of natriuretic and many other vasoactive 
peptides, in addition to blocking angiotensin-II-type-1 receptors, would reduce CV 
morbidity and mortality in patients with HFrEF compared to an ACEI used in guideline-
recommended doses (3). Patients aged >18 years with chronic HFrEF (EF <35-40%) and 
NYHA functional class II-IV symptoms, an elevated BNP or NT-proBNP, an eGFR >30 
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mL/min/1.73 m2, and a stable dose of a β-blocker and an ACEI/ARB equivalent to at 
least 10 mg of enalapril daily were eligible for enrollment.  
A total of 10,521 patients entered sequential single-blind run-in periods with 
enalapril 10 mg twice daily for 2 weeks followed by sacubitril/valsartan initially at a dose 
of 100 mg (i.e. currently marketed as 49/51 mg tablet) twice daily uptitrated to 200 mg 
(i.e. 97/103 mg tablet) twice daily for 4 to 6 weeks. Following the run-in phase, 8442 
patients (80%) who had tolerated both interventions and who were still willing and able 
to participate were randomized in a 1:1 fashion to double-blind treatment with either 
enalapril 10 mg twice daily or sacubitril/valsartan 200 mg twice daily (7). 
 
Efficacy of Sacubitril/Valsartan 
On March 28, 2014 after the third interim analysis, the data and safety monitoring 
board notified the principal investigators that the boundary for overwhelming benefit had 
been crossed and the executive committee voted to stop the trial early (4). At the time the 
study was terminated, enrollment had been completed and there was a median follow-up 
duration of 27 months. Patients receiving sacubitril/valsartan (914 events, 21.8%), 
compared to enalapril (1117 events, 26.5%), were at lower risk for the primary outcome, 
death due to CV causes or first hospitalization for HF (Hazard Ratio [HR] 0.80, 95% 
Confidence Interval [CI] 0.73-0.87; p-value <0.001), as well as each of the components 
of the composite endpoint (Figure 1). Treatment with sacubitril/valsartan (711 events, 
17.0%) vs. enalapril (835 events, 19.8%) also led to a significant reduction in all-cause 
mortality (HR 0.84, 95% CI 0.76-0.93; p-value = <0.001). Based on the PARADIGM-HF 
data and actuarial estimates of event rates and life expectancy, it has been projected that 
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treatment with sacubitril/valsartan would prolong survival an average of 1 to 2 years 
across a wide range of age groups (8).  
Although health-related quality of life, as assessed by the change in the KCCQ 
clinical summary score from baseline to 8 months, declined in both treatment arms during 
follow-up, it worsened to a greater extent in the enalapril arm (9). However, when zero 
values were not imputed for patients who died, the magnitude of the between-group 
difference (0.95 points, 95% CI 0.31-1.59; p-value = 0.004) was greatly diminished 
suggesting that the KCCQ analyses were confounded by the competing risk of death. 
Additional research is required to evaluate the impact of ARNI therapy on health-related 
quality of life and functional capacity. 
 
Safety and Tolerability of Sacubitril/Valsartan 
 Patients receiving sacubitril/valsartan experienced higher rates of symptomatic 
hypotension vs. enalapril (14.0% vs. 9.2%, p-value = <0.001). (Figure 2) (10). However, 
there were no differences between the sacubitril/valsartan and enalapril groups in 
permanent study drug discontinuation due to hypotension (0.9% vs. 0.7%, p-value = 
0.38). The incidence of renal insufficiency (i.e. defined as a serum creatinine >2.5 
mg/dL) and hyperkalemia during follow-up was lower in patients treated with 
sacubitril/valsartan compared to enalapril. In addition, the occurrence of minor and life-
threatening episodes of angioedema was low (<0.5%) and did not differ between 
treatment groups. Of note, as a condition for approval, the FDA has required Novartis 
Pharma AG (Basel, Switzerland) to conduct an observational registry to further clarify 
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the risk of angioedema in black patients treated with sacubitril/valsartan vs. conventional 
RAS inhibitors (New Drug Application 207620 Approval, accessdata.fda.gov).  
Finally, because neprilysin plays a role in removing amyloid-β peptides from the 
brain, it has been postulated that long-term treatment with an ARNI might affect 
cognitive function (11). Despite this theoretical concern, neprilysin is only one of more 
than 20 enzymes involved in amyloid-β clearance. There was no discernible signal of 
increased risk of dementia with sacubitril/valsartan, compared to enalapril, in the 
PARADIGM-HF trial. However, additional research is required to evaluate the 
association between treatment with sacubitril/valsartan and mild cognitive impairment in 
patients with additional risk factors for dementia as well as over a longer duration of 
follow-up (12). Thus, as part of the FDA approval process, the manufacturer will conduct 
a multicenter, randomized, double-blind, active-controlled trial to evaluate the effects of 
sacubitril/valsartan vs. valsartan on cognitive function as assessed by comprehensive 
neurocognitive testing and brain imaging (New Drug Application 207620 Approval, 
accessdata.fda.gov).  
 
Real-World Adoption of Sacubitril/Valsartan 
 Despite receiving FDA approval and strong recommendations in international 
guidelines, the uptake of sacubitril/valsartan in routine practice has been disappointing. 
The American Heart Association’s GWTG-HF registry found that based on FDA 
labeling, nearly 70% of patients hospitalized for HFrEF (i.e. EF <40%) would be eligible 
for sacubitril/valsartan (13). Similarly, data from the United Kingdom suggest that 
upwards of 60% of outpatients consecutively referred to a community HF clinic would be 
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eligible for ARNI therapy (14). In contrast, only 2.3% of patients hospitalized for HFrEF 
were prescribed sacubitril/valsartan at discharge in the first 12 months following FDA 
approval (15). Some estimates suggest that optimal implementation of ARNI therapy 
could prevent more than 28,000 deaths per year (16). Given the relative efficacy and 
safety profile of sacubitril/valsartan compared to conventional RAS inhibitors, it is 
important to carefully consider provider reasons for not prescribing, system level barriers 
to implementation, and patient factors for decision making with respect to this life-
prolonging therapy. 
 
Stability on Traditional RAS Inhibitors 
There is a clinical inertia among providers and a resistance to change among 
patients if things seem to be going well and the situation is stable (17). However, the 
PARADIGM-HF trial found that HF is a lethal syndrome, regardless of the severity of 
symptoms, as evidenced by the high short-term mortality rate seen in a minimally 
symptomatic patient population. Despite the fact that nearly 40% of patients had no prior 
hospitalization for HF, one in five of these patients died due to CV causes or were 
hospitalized for HF during follow-up (18). In addition to improving survival, 
sacubitril/valsartan, compared to enalapril, reduced the risk of clinical deterioration 
including hospitalizations (HR 0.79, 95% CI 0.71-0.89; p-value <0.001), emergency 
department visits (HR 0.66, 95% 0.52-0.58; p-value = 0.001), and/or intensification of 
medical therapy in the outpatient setting (HR 0.84, 95% 0.74-0.94; p-value = 0.003) for 
worsening HF (19, 20). Similarly, among patients recently admitted for a primary 
diagnosis of HF, readmission for any cause (OR 0.74, 95% CI 0.56-0.97; p-value = 
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0.031) and/or for HF (OR 0.62, 95% CI 0.45-0.87; p-value = 0.006) at 30-days were 
lower in the sacubitril/valsartan arm (21). Thus, given the dissociation between HF signs 
and symptoms and prognosis and the overwhelming benefit of sacubitril/valsartan on 
both fatal and non-fatal endpoints, there is not a clear rationale to wait for clinical 
progression or deterioration before switching patients from traditional RAS inhibitors to 
an ARNI. 
 
Validity of the PARADIGM-HF Trial 
 Another potential reason for clinical aversion to switching patients to  
sacubitril/valsartan may be reservations regarding the design of the PARADIGM-HF trial 
(22). It has been argued that enalapril and/or the target dose used in the PARADIGM-HF 
trial were not the gold standard comparator. However, this is the only dose of any ACEI 
that has been shown in a clinical trial to improve long-term survival (23). Although 
CONSENSUS tested a higher target dose of enalapril (i.e. 40 mg daily), less than 25% of 
patients reached the highest dose and the mean daily dose of enalapril achieved in 
PARADIGM-HF was actually marginally higher (i.e. 18.9 mg vs. 18.6 mg) (24, 25). 
Thus, any difference between sacubitril/valsartan and enalapril in terms of outcomes is 
likely to be due to the addition of neprilysin inhibition.  
 
Reproducibility of the PARADIGM-HF Trial 
It has also been argued that PARADIGM-HF was a single trial and the results 
need to be replicated before ARNI therapy supplants traditional RAS inhibitors as the 
standard of care. However, the idea of carrying out a hypothetical PARADIGM-HF-2 
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may be both unethical and unnecessary. If PARADIGM-HF was divided at the 
chronological midpoint into two distinct clinical trials and the results reexamined, despite 
the loss of statistical power, the outcomes of both smaller trials would be identical to the 
parent trial (22). The statistical power of PARADIGM-HF was equal to or greater than 
that of four separate clinical trials each showing a reduction in CV mortality with a p-
value <0.05. The possibility that the primary results were due to chance is less than one in 
one million (26). This assertion is further substantiated by a meta-analysis of pooled data 
from three clinical trials in HFrEF (i.e. IMPRESS, OVERTURE, and PARADIGM-HF) 
which found that combined neprilysin-RAS inhibition (i.e. omapatrilat or 
sacubitril/valsartan) compared to traditional RAS inhibition improved survival (27).  
 
Cost Considerations with Sacubitril/Valsartan 
Another patient and system level barrier to implementation and widespread 
adoption of sacubitril/valsartan is cost (28). The estimated wholesale price of twice-daily 
dosing of sacubitril/valsartan in the United States is $12.50 per day costing upwards of 
$4500 annually (29). However, it is difficult to estimate true out-of-pocket expenses as 
there is tremendous variation based on insurance status and level of reimbursement. In 
addition, obtaining approval for even partial reimbursement may require clear 
documentation in the medical record and paperwork for prior authorization, placing an 
additional burden on prescribers.  
In contrast, although the cost of the therapy may be substantial for patients and 
healthcare payers, it should be pointed out that several analyses have found 
sacubitril/valsartan to be cost-effective compared to conventional RAS inhibitors (i.e. 
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traditionally defined as less than $50,000 per quality-adjusted life year) in HFrEF patients 
with NYHA functional class II-IV symptoms (30-32).  
 
The Use of Sacubitril/Valsartan in Primary Care 
 Although the 2016 ACC/AHA/HFSA focused update recommends ARNI therapy 
as a first-line alternative to traditional RAS inhibitors in patients with HFrEF who remain 
symptomatic despite optimal medical therapy (5, 6), the American Academy of Family 
Physicians has not yet endorsed this guideline because of concerns about its methodology 
and insufficient evaluation of harm (33). Due to their advanced age and multiple 
comorbidities, it is not uncommon for HFrEF patients to receive regular care from 
general practitioners and multiple specialists and subspecialists. Many primary care 
physicians may treat a significant number of patients with HFrEF and some may be the 
primary provider for HF-related care in addition to general medical conditions. It is 
confusing and counterproductive to general practitioners when a discrepancy exists 
between the guideline recommendations published by cardiologists and HF specialists 
and the public statements issued by their own professional societies. As a result, 
increasing the uptake of sacubitril/valsartan in the outpatient setting may require 
providing continuing medical education focused on the specific needs and concerns of 
primary care physicians. The experience with sacubitril/valsartan is a learning 
opportunity and moving forward guideline committees addressing topics in cardiology 
and HF should include physicians with training in internal and/or family medicine who 
are currently practicing and selected to represent the viewpoint and serve as a liaison for 
their respective professional organizations.  
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LIFE 
 Although sacubitril/valsartan was broadly approved by the FDA for the 
management of patients with HFrEF (i.e. defined as EF <40%) and NYHA functional 
class II-IV symptoms, it is noteworthy that only 33 patients (0.8%) with NYHA 
functional class IV symptoms were randomized to sacubitril/valsartan. Thus, the LIFE 
study (ClinicalTrials.gov Identifier: NCT02816736) is a randomized, double-blind, 
active-controlled trial designed to assess the efficacy, safety, and tolerability of 
sacubitril/valsartan in a planned 400 patients with HFrEF and severe symptoms. Patients 
are eligible for enrollment if they have advanced HFrEF defined as an EF <35% and 
NYHA functional class IV symptoms (i.e. chronic dyspnea or fatigue at rest or with 
minimal exertion) or requiring chronic inotropic therapy, an elevated BNP or NT-
proBNP, and one or more enrichment criteria. Patients are randomized to 
sacubitril/valsartan vs. valsartan titrated to the maximally-tolerated dose and followed for 
24 weeks. The primary endpoint is the proportional change from baseline in the area 
under the curve for NT-proBNP levels at weeks 4, 8, 12, and 24. 
 Although it is difficult to define advanced HF, the LIFE trial requires one or more 
enrichment criteria as objective evidence of advanced HF including need for inotropic 
support, repeat hospitalizations, and assessments of functional capacity. In addition, both 
treatment arms in the LIFE trial differ in clinically important ways compared to 
PARADIGM-HF. First, the LIFE trial will make use of a lower dose of 
sacubitril/valsartan (i.e. 24/26 mg tablet by mouth twice daily), which was not used in 
PARADIGM-HF. This will allow a better assessment of the safety and tolerability of this 
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lower dose, particularly with respect to symptomatic hypotension. Second, the 
comparator arm is valsartan, an ARB, as opposed to enalapril, the gold standard ACEI. 
This will potentially allow a more direct interpretation of the effects of neprilysin 
inhibition in isolation. However, it should be noted that the selection of valsartan for the 
control arm has been criticized given the limited experience with ARBs in HFrEF 
patients with NYHA functional class IV symptoms compared to ACEIs. Despite these 
strengths, the primary endpoint of the LIFE trial will assess time-averaged change in a 
surrogate biomarker (i.e. NT-proBNP). While natriuretic peptide levels are strongly 
correlated with adverse events (34), the trial will be underpowered to draw definitive 
conclusions on hard clinical outcomes. In addition, recruitment may be challenging given 
that one of the first harbingers of advanced HF is an inability to tolerate guideline-
directed medical therapies.  
 
PIONEER-HF 
 The PIONEER-HF study (ClinicalTrials.gov Identifier: NCT02554890) is a 
multicenter trial designed to assess the role of sacubitril/valsartan in patients with HFrEF 
stabilized during hospitalization for worsening HF. Patients are eligible for enrollment no 
earlier than 24 hours and up to 10 days from initial presentation for a primary diagnosis 
of HF if they have an EF <40%, an elevated BNP or NT-proBNP, and are clinically 
stable (i.e. defined as an SBP >100 mmHg and no recent intensification in IV therapies). 
Patients are randomized 1:1 to in-hospital initiation of sacubitril/valsartan vs. enalapril 
titrated to target dose over 8 weeks of double-blind treatment and 4 weeks of open-label 
sacubitril/valsartan using an algorithm based on SBP. The primary endpoint of 
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PIONEER-HF is the time-average proportional change in NT-proBNP from baseline 
through weeks 4 and 8. Secondary and exploratory endpoints include urgent and 
emergent episodes of care and serum and urinary biomarkers of myocardial stress, 
cardiac fibrosis/remodeling, inflammation, and tissue perfusion/injury. 
 There are several unique aspects of the PIONEER-HF study which will further 
explore the application of sacubitril/valsartan in routine practice. Of note, PIONEER-HF 
was designed to enroll patients hospitalized for worsening HF following stabilization 
irrespective of duration of diagnosis or background HF therapy and without a preceding 
run-in period. Thus, this will be the first opportunity to assess the safety and tolerability 
of in-hospital initiation of sacubitril/valsartan in de novo HF and in a treatment naïve 
patient population. In addition, the secondary endpoints of PIONEER-HF move beyond 
traditional outcome measures by incorporating worsening HF treated in the outpatient 
setting including unscheduled office, urgent care, and ER visits. The available data 
suggest that including unscheduled or urgent episodes of care not leading to 
hospitalization in the composite clinical endpoint may increase the total number of 
accrued events by upwards of 15% (20). Finally, the biomarker data may provide 
valuable insights into the mechanism of action of sacubitril/valsartan and the 
pathophysiology of HF.  
 
HEART FAILURE WITH A PRESERVED EJECTION FRACTION 
PARAMOUNT and PARAGON-HF 
 The PARAMOUNT trial was designed to assess the therapeutic value of 
sacubitril/valsartan in HFpEF (35). Patients were eligible if they had an EF >45% and a 
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history of HF with associated signs and symptoms and an elevated NT-proBNP. 
Following a run-in phase, 301 patients were randomized 1:1 in a double-blind fashion to 
treatment with valsartan 160 mg twice daily (n = 152) or sacubitril/valsartan 200 mg 
twice daily (n = 149). The PARAMOUNT trial was continued for 36 weeks including the 
12-week main study period and a 24-week extension phase. The primary efficacy 
endpoint was change in NT-proBNP from baseline to week 12.  
 Treatment with sacubitril/valsartan, compared to valsartan, led to an early and 
sustained reduction in NT-proBNP through week 12. Although NT-proBNP levels 
continued to decrease in patients treated with sacubitril/valsartan, the between-group 
difference was no longer statistically significant at 36 weeks (p-value = 0.20). In addition, 
after 36 weeks of treatment with sacubitril/valsartan, compared to valsartan, left atrial 
volume and dimension were both significantly reduced. However, there was no 
difference in EF, ventricular volumes, or other diastolic parameters. Patients treated with 
sacubitril/valsartan also experienced an improvement in NYHA functional class at 36 
weeks compared to the valsartan arm. PARAGON-HF (ClinicalTrials.gov Identifier: 
NCT01920711), a CV outcomes trial of sacubitril/valsartan in HFpEF, has fully enrolled 
over 4800 patients with a planned follow-up duration of up to 57 months for the 
composite endpoint of CV mortality and total hospitalizations for worsening HF (36).  
Although the results of the PARAGON-HF trial are highly anticipated, it is 
notoriously difficult to make the assessment that dyspnea in a patient with a preserved EF 
is due to HF and not a comorbid condition (i.e. obesity, COPD, sleep disordered 
breathing, etc.). The experience with the TOPCAT study further highlights the challenges 
of designing and conducting global clinical trials in HFpEF (37, 38). In short, the 
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TOPCAT investigators found tremendous geographic variation in patient characteristics, 
outcomes, and response to therapy that may have been partially explained by differential 
regional enrollment in the prior hospitalization vs. BNP strata (39, 40). As a result, it is 
notable that participation in PARAGON-HF is contingent upon the presence of signs and 
symptoms of HF requiring treatment with a diuretic, evidence of structural heart disease 
(i.e. defined as left atrial enlargement and/or left ventricular hypertrophy), and an 
elevated NT-proBNP in order to improve diagnostic accuracy and enroll a sufficiently 
high-risk patient population. In contrast to prior pivotal trials in HFpEF, the control arm 
of PARAGON-HF is an active comparator (i.e. valsartan) as opposed to placebo as ARBs 
are commonly prescribed and have been shown to be safe in HFpEF and may lead to a 
modest reduction in hospitalizations for worsening HF (41). In addition, the use of an 
active comparator will allow the neurohormonal benefits of neprilysin inhibition to be 
studied in isolation from RAS blockade in HFpEF. The major limitation of the 
PARAGON-HF trial is that requiring objective evidence of structural heart disease and an 
elevated NT-proBNP may limit its generalizability. It is well-established that upwards of 
30% of patients with symptomatic HFpEF may have a normal BNP in the setting of an 
elevated pulmonary capillary wedge pressure (42). In addition, prior research has shown 
that although elevated BNP/NT-proBNP levels may denote an overall higher risk HFpEF 
cohort, these patients may be less responsive to treatment (43, 44). Thus, there may be a 
dissociation between disease severity and response to therapy in HFpEF which requires 
further exploration. Regardless, the PARAGON-HF trial will determine whether the 
short-term effects of sacubitril/valsartan on cardiac injury (45), myocardial stress, and left 
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atrial remodeling translate into improved long-term prognosis in an adequately powered 




 The PARADISE-MI trial (ClinicalTrials.gov Identifier: NCT02924727) will test 
the hypothesis that ARNI therapy will reduce CV morbidity and mortality compared to 
conventional RAS inhibition in patients post-MI with additional risk factors. PARADISE-
MI will enroll patients diagnosed with a spontaneous acute MI with an EF <40% and/or 
pulmonary congestion requiring IV therapy, one or more enrichment criteria, and 
documented hemodynamic stability. An estimated 4650 patients will be randomized 1:1 
to double-blind treatment with sacubitril/valsartan vs. rampiril and followed for the 
composite of CV mortality, hospitalization for worsening HF, and HF treated in the 
outpatient setting. 
 The PARADISE-MI trial follows a strong precedent whereby traditional RAS 
inhibitors were first studied in the setting of chronic HF and later found to be equally 
beneficial in post-MI patients with evidence of systolic dysfunction and/or signs and 
symptoms of HF (46-50). However, due to the widespread availability of early 
revascularization and advances in medical therapy, the incidence of previously 
asymptomatic patients experiencing a MI complicated by a reduced EF and/or pulmonary 
edema has declined dramatically over time. For example, in a national quality 
improvement registry of patients admitted for acute coronary syndrome, less than 20% of 
patients had a moderately-severely reduced EF (i.e. <40) (51). Thus, although the 
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enrichment criteria will likely be necessary to identify patients at sufficiently high-risk to 
ensure an adequately powered study, this requirement may also make it more challenging 
to recruit patients and limit the generalizability of the findings. 
 
HYPERTENSION 
 The combination of neprilysin inhibition and RAS blockade has also been 
explored as a treatment for hypertension. In a phase II study 1328 patients with mild-to-
moderate essential hypertension were randomized to sacubitril/valsartan, valsartan, or 
placebo (52). After 8 weeks of treatment, sacubitril/valsartan, compared to the 
appropriate comparator dose of valsartan, led to a greater reduction in mean DBP (-2.17 
mmHg, 95% CI -3.28 mmHg, -1.06 mmHg; p-value = 0.0023). The difference was 
significant for all pairwise comparisons except for the lowest dose of sacubitril/valsartan 
vs. valsartan. 
 Despite the strong evidence-basis for aggressive BP control in high-risk 
individuals, epidemiologic data suggest that the standard BP goal is achieved in only 50% 
of patients (53). Thus, treating hypertension to achieve goal BP remains an important 
public health objective and an unmet therapeutic need. Given the demonstrated 
superiority of ARNI therapy compared to conventional RAS inhibitors as an anti-
hypertensive agent, pivotal trials should be designed and conducted to study the efficacy 
and safety of sacubitril/valsartan as a monotherapy and as part of combination therapy in 
patients with hypertension and risk factors for CVD as well as medically refractory 
hypertension (54).     
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CONCLUSION 
 Despite major therapeutic advances in the management of CVD, patients post-MI 
with evidence of systolic dysfunction or symptomatic HF irrespective of EF receiving 
optimal medical therapy including traditional RAS inhibitors remain at high-risk for CV 
morbidity and mortality. The PARADIGM-HF trial demonstrated that ARNI therapy, 
compared to an ACEI, led to a robust benefit on both fatal and non-fatal endpoints 
independent of baseline risk and current clinical status in patients with HFrEF and 
predominantly mild symptoms. Thus, the available data suggest there is little rationale to 
wait for clinical progression or deterioration and it is reasonable to switch stable HFrEF 
patients with minimal symptoms from an ACEI or an ARB to an ARNI. Ongoing phase 
IV clinical trials promise to clarify the efficacy, safety, and tolerability of 
sacubitril/valsartan in HFrEF patients with NYHA functional class IV symptoms and/or 
hospitalized for acute decompensated HF. In addition, the role of ARNI therapy in the 
post-MI setting and in the management of patients with HFpEF is being evaluated in 
well-powered CV outcome trials. Future research should clarify the potential scope of 
sacubitril/valsartan across the spectrum of CVD including subgroups of interest such as 
patients with HTN and additional risk factors, diabetes mellitus, and chronic kidney 
disease.
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Figure Legends 
Figure 1. Forest plots for the primary, secondary, and exploratory outcomes of the 
PARADIGM-HF trial. 
Figure 2. The incidence of adverse events occurring during the PARADIGM-HF trial.
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To reduce the risk of CV death and hospitalization for HF 
in patients with chronic HF (NYHA functional class II-IV) 
and reduced EF 
Mechanism of Action  
• Sacubitril: Prodrug that inhibits neprilysin and 
increases circulating levels of natriuretic peptides  
• Valsartan: Antagonist of the angiotensin II receptor  
Dosage Forms and Strengths  
24/26 mg (50 mg), 49/51 mg (100 mg), and 97/103 mg 
(200 mg) 
Dosage and Administration  
• The recommended starting dose is 49/51 mg twice-
daily 
• Reduce the starting dose to 24/26 mg twice-daily for 
patients not currently taking or previously taking a low 
dose of an ACEI or ARB2 
• Double the dose every 2 to 4 weeks to the target 
maintenance dose of 97/103 mg twice-daily as 
tolerated 
• If switching from an ACEI allow a washout period of  
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  36 hours between administrations of the two drugs. 
Contraindications  
• Hypersensitivity to any component  
• History of angioedema related to prior ACEI or ARB 
therapy 
• Concomitant use with an ACEI 
Adverse Reactions3  




2Defined as <10 mg/day of enalapril or an equivalent dose of another ACEI or ARB 
3Incidence >5% 
 
Abbreviations: CV = cardiovascular; HF = heart failure; NYHA = New York Heart Association; EF = ejection fraction; mg = 
milligram; ACEI = angiotensin converting-enzyme inhibitor; ARB = angiotensin receptor blocker.
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Table 2. Guideline recommendations for the use of ARNIs in patients with HFrEF. *Level of evidence for an ARNI. 
 
2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure 
 
COR LOE RECOMMENDATION    
I B-R* 
The clinical strategy of inhibition of the renin-angiotensin system with ACEIs OR 
ARBs OR ARNI in conjunction with evidence-based β-blockers and aldosterone 
antagonists in select patients is recommended for patients with chronic HFrEF 
to reduce morbidity and mortality. 
I B-R 
In patients with chronic symptomatic HFrEF NYHA class II or III who tolerate an 
ACEI or ARB, replacement by an ARNI is recommended to further reduce morbidity 
and mortality. 
III B-R 
ARNI should not be administered concomitantly with an ACEI or within 36 hours of  
the last dose of an ACEI. 
III C-EO ARNI should not be administered to patients with a history of angioedema. 
 
2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 
 
I A 
An ACEI is recommended in addition to a β-blocker, for symptomatic patients with 
HFrEF to reduce the risk of HF hospitalization and death. 
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I B 
Sacubitril/valsartan is recommended as a replacement for an ACEI to further reduce  
the risk of HF hospitalization and death in ambulatory patients with HFrEF who  
remain symptomatic despite optimal treatment with an ACEI, β-blocker, and 
mineralocorticoid receptor antagonist. 
I B 
An ARB is recommended to reduce the risk of HF hospitalization and CV death in 
symptomatic patients unable to tolerate ACEI (patients should also receive a β-
blocker and an MRA). 
IIb C 
An ARB may be considered to reduce the risk of HF hospitalization and death in 
patients who are symptomatic despite treatment with a β-blocker who are unable to 
tolerate an MRA. 
 
Abbreviations: ACC = American College of Cardiology; AHA = American Heart Association; HFSA = Heart Failure Society of 
America; COR = class (strength) of recommendation; LOE = level of evidence; R = randomized; EO = expert opinion; ACEI = 
angiotensin converting-enzyme inhibitor; ARB = angiotensin receptor blocker; ARNI = angiotensin receptor-neprilysin inhibitor; 
HFrEF = Heart Failure with a Reduced Ejection Fraction; NYHA = New York Heart Association; CV = cardiovascular. 
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Table 3. Select completed and ongoing clinical trials of sacubitril/valsartan in CVD. 
 
 
Trial Sample Size Study Population Enrollment Criteria Active Comparator2 Primary Endpoint 
PARADIGM-HF1 8442 HFrEF 
• Chronic HF with an EF <40% 
• NYHA II-IV 
• Elevated BNP or NT-proBNP 
• Stable dose of ACEI/ARB equivalent 
to >10 mg of enalapril daily 
Enalapril 10 mg  CVM+First HF Hospitalization 
LIFE 400 HFrEF, NYHA IV 
• Chronic HF with an EF <35% 
• NYHA IV 
• Minimum of 3 months of GDMT 
• SBP >90 mmHg 
• Elevated BNP or NT-proBNP 
• >1 Enrichment Criteria3 
Valsartan 160 mg  NT-proBNP over 24 weeks 
PIONEER-HF 736 Hospitalized HFrEF 
• Chronic HF with an EF <40% 
• Admitted >24 hrs 
• Elevated BNP or NT-proBNP  
Enalapril 10 mg  NT-proBNP over 8 weeks 
   • SBP >100 mmHg   
   • Stable IV Diuretics for Prior 6 hrs   
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   • No Recent IV Vasodilators and/or   
   Inotropes   
PARAMOUNT1 301 HFpEF 
• Chronic HF with an EF >45%  
• Elevated NT-proBNP 
• Chronic Oral Diuretic Therapy 
• SBP <140 mmHg or <160 mmHg on 
>3 anti-HTN Agents 
Valsartan 160 mg  NT-proBNP over 12 weeks 
PARAGON 4500 HFpEF 
• Chronic HF with an EF >45% 
• Elevated NT-proBNP 
• Chronic Oral Diuretic Therapy,  
• Structural Heart Disease (i.e. Left 
Atrial Enlargement or Left 
Ventricular Hypertrophy) 
Documented on Echocardiogram 
Valsartan 160 mg  
CVM+Total HF 
Hospitalizations 
PARADISE-MI 4650 High-Risk Post-MI 
• Spontaneous MI between 12 hrs and 
7 days 
• EF <40% or Pulmonary Congestion 
Requiring IV Therapy 
Ramipril 5 mg 
Time to CVM+HF 
Hospitalization+Outpatient HF 
   • Hemodynamic Stability   
   • >1 Risk Factor4   




3Current inotropic therapy or use of inotropes in the past 6 months, >1 hospitalizations for HF excluding index admission (6 months), 
EF <25% (12 months), Peak VO2 <55% predicted or peak VO2 <16 for men or <14 for women (RER >1.05) (6 months), 6-MWT 
Distance <300 m (3 months) 
4Age >70 years, eGFR <60 mL/min/1.73 m2, History of DM type I or type II, History of Prior MI, Documented Afib During Index 
Admission, EF <30%, Worst Killip Class III or IV Requiring IV Therapy, and/or STEMI Without Reperfusion 
 
Abbreviations: CVD = cardiovascular disease; HF = heart failure; EF = ejection fraction; HFrEF = heart failure with a reduced 
ejection fraction; HFpEF = heart failure with a preserved ejection fraction; NYHA = New York Heart Association; BNP = b-type 
natriuretic peptide; NT-proBNP = amio terminal prob-type natriuretic peptide; ACEI = angiotensin converting-enzyme inhibitor; ARB 
= angiotensin receptor blocker; mg = milligrams; CVM = cardiovascular mortality; eGFR = estimated glomerular filtration rate; 
GDMIT = guideline-directed medical therapy; SBP = systolic blood pressure; hrs = hours; IV = intravenous; HTN = hypertension; MI 
= myocardial infarction; VO2 = oxygen consumption; RER = respiratory exchange ratio; 6-MWT = 6-minute walk test; DM = diabetes 
mellitus; afib = atrial fibrillation; STEMI = ST-elevation myocardial infarction.  
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Figure 1 
Abbreviations: CV = cardiovascular; HF = heart failure; ER = emergency room. 
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Figure 2 
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Abbreviations: p = probability value; SBP = systolic blood pressure; NS = not significant 
 
